Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Earnings for Trevena, Inc. (TRVN)
Earnings in 2023 (TTM): $-39,971,000
According to Trevena, Inc.'s latest financial reports the company's current earnings (TTM) are $-39,971,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Trevena, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-39,971,000 | $-40,289,000 |
| 2022 | $-53,670,000 | $-53,667,295 |
| 2021 | $-51,588,000 | $-51,160,000 |
| 2020 | $-29,069,000 | $-29,369,000 |
| 2019 | $-24,871,000 | $-28,056,000 |
| 2018 | $-30,039,000 | $-30,784,000 |
| 2017 | $-71,865,000 | $-71,865,000 |
| 2016 | $-102,994,000 | $-102,994,000 |
| 2015 | $-50,528,240 | $-50,528,240 |
| 2014 | $-49,700,875 | $-49,700,875 |
| 2013 | $-23,251,435 | $-23,251,435 |
| 2012 | $-15,635,658 | $-15,635,658 |
| 2011 | $-15,810,004 | $-15,810,004 |